BOSTON A company that markets a heart medication targeted at African-Americans will merge with a Cambridge, Mass.-based biotech.
NitroMed, which markets the drug BiDil, will merge with Archemix Corp. The new company will keep the Archemix name and Cambridge headquarters.
BiDil is known generically as isosorbide dinitrate and hydralazine hydrochloride. It is a prescription drug.